New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - olsalazine sodium 250mg - capsule - 250 mg - active: olsalazine sodium 250mg excipient: gelatin magnesium stearate opacode black s-1-17822 opacode black s-1-17823 - maintenance of patients with ulcerative colitis in remission. treatment of acute ulcerative colitis of mild to moderate severity with or without the concomitant use of steroids.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - penicillamine 250mg - tablet - 250 mg - active: penicillamine 250mg excipient: glycerol hypromellose microcrystalline cellulose povidone purified water   sodium starch glycolate stearic acid titanium dioxide - severe, active rheumatoid arthritis. as a chelating agent in the treatment of wilson's disease and lead poisoning. d-penamine will enhance the urinary excretion of gold and mercury and other heavy metals. in the treatment of cystinuria in cases where high-fluid regimens are not adequate, or in conjunction with them.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - mycophenolate mofetil 250mg;   - capsule - 250 mg - active: mycophenolate mofetil 250mg   excipient: croscarmellose sodium gelatin   hyprolose indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc sodium laurilsulfate   tekprint black sw-9008 titanium dioxide   water   - myaccord is indicated for the prophylaxis of acute organ rejection in patients receiving allogeneic renal transplants.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 250mg;  ;   - dispersible tablet - 250 mg - active: deferasirox 250mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flucloxacillin sodium monohydrate 250mg;   - powder for injection - 250 mg - active: flucloxacillin sodium monohydrate 250mg  

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - flutamide 250mg;   - tablet - 250 mg - active: flutamide 250mg   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified water sodium laurilsulfate - for the palliative treatment of advanced prostatic cancer in previously untreated patients or those who have not responded or who have become refractory to hormonal manipulation. as a component of the treatment used in the management of locally advanced prostatic carcinoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - teriparatide 250 µg/ml (rhpth(1-34));   - solution for injection - 250 mcg/ml - active: teriparatide 250 µg/ml (rhpth(1-34))   excipient: glacial acetic acid hydrochloric acid mannitol metacresol sodium acetate sodium hydroxide water for injection - forteo, in combination with calcium and vitamin d, is indicated for the treatment of osteoporosis in postmenopausal women and in men at high risk of fracture.

New Zealand - English - Medsafe (Medicines Safety Authority)

leo pharma limited - sodium fusidate 250mg; sodium fusidate 250mg - film coated tablet - 250 mg - active: sodium fusidate 250mg excipient: colloidal silicon dioxide crospovidone gelatin hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide active: sodium fusidate 250mg excipient: colloidal silicon dioxide crospovidone dl-alpha tocopheryl acetate hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified talc titanium dioxide - treatment of localised as well as generalised staphylococcal infections (e.g. abscesses, furunculosis, wound infections, pneumonia, peritonitis, osteomyelitis, septicaemia, enteritis and otorhinolaryngeal infections).

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - gefitinib 250mg - coated tablet - 250 mg - active: gefitinib 250mg excipient: croscarmellose sodium ethanol hypromellose iron oxide red iron oxide yellow lactose monohydrate macrogol 300 magnesium stearate microcrystalline cellulose povidone purified water sodium laurilsulfate titanium dioxide - treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) whose tumours express activating mutations of the egfr tyrosine kinase.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 250mg;  ; clarithromycin 250mg - film coated tablet - 250 mg - active: clarithromycin 250mg   excipient: croscarmellose sodium hydrated silica hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc quinoline yellow   sorbic acid sorbitan oleate starch stearic acid titanium dioxide vanillin active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium ethanol   hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc purified water quinoline yellow   sorbic acid sorbitan oleate starch stearic acid titanium dioxide vanillin - klacid tablets are indicated for treatment of infections caused by susceptible organisms. such infections include: · respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. · skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. · disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum, or mycobacterium kansasii. · prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. · clarithromycin in the presence of acid suppression is indicated for the treatment of duodenal ulcer and in reducing the rate of ulcer recurrence.